A novel production system based on the Isotope Separation On-Line (ISOL) method is being developed to produce intense mass separated 11 C beams for PET-aided hadron therapy. In this work, we present a systematic study of the target that was developed for optimized 11 C beam production. A solid boron nitride target (BN) with approximately 21% open porosity was manufactured by spark plasma sintering to provide maximized in-target production yield with enhanced isotope release properties. Operational limitations with respect to high temperatures and oxidizing atmospheres were studied, revealing that the BN target can withstand temperatures up to 1500 • C and can be operated with a controlled O 2 leak, providing O 2 potentials up to −300 kJ/mol, measured at 1000 • C.

The method of laser spectroscopy in supersonic gas jets was proposed for high-resolution and highefficiency in-gas laser ionization and spectroscopy studies of short-lived nuclei. The flow properties of such supersonic gas jets have been characterized under off-line conditions. Planar laser-induced fluorescence spectroscopy of seeded copper atoms has been applied to nonintrusively measure velocity, temperature, and relative density profiles of gas jets formed by different de Laval nozzles. For validation, planar laserinduced fluorescence spectroscopy was applied on supersonic free jets with well-known flow parameters. The performance of the in-gas-jet laser spectroscopy method is determined by the achievable spectral resolution, which requires an optimization and a precise manufacturing of the nozzle inner contour as well as a pressure matching of the background medium at the nozzle exit. Our studies now enable a thorough understanding and quantification of these requirements and a determination of the final performance of the in-gas-jet method. Additionally, a comparison between the experimental results and the numerical calculations was performed for the temperature, velocity, and Mach number profiles of underexpanded and quasiuniform jets formed by a de Laval nozzle.

The CERN-MEDICIS (MEDical Isotopes Collected from ISolde) facility has delivered its first radioactive ion beam at CERN (Switzerland) in December 2017 to support the research and development in nuclear medicine using non-conventional radionuclides. Since then, fourteen institutes, including CERN, have joined the collaboration to drive the scientific program of this unique installation and evaluate the needs of the community to improve the research in imaging, diagnostics, radiation therapy and personalized medicine. The facility has been built as an extension of the ISOLDE (Isotope Separator On Line DEvice) facility at CERN. Handling of open radioisotope sources is made possible thanks to its Radiological Controlled Area and laboratory. Targets are being irradiated by the 1.4 GeV proton beam delivered by the CERN Proton Synchrotron Booster (PSB) on a station placed between the High Resolution Separator (HRS) ISOLDE target station and its beam dump. Irradiated target materials are also received from external institutes to undergo mass separation at CERN-MEDICIS. All targets are handled via a remote handling system and exploited on a dedicated isotope separator beamline. To allow for the release and collection of a specific radionuclide of medical interest, each target is heated to temperatures of up to 2,300°C. The created ions are extracted and accelerated to an energy up to 60 kV, and the beam steered through an off-line sector field magnet mass separator. This is followed by the extraction of the radionuclide of interest through mass separation and its subsequent implantation into a collection foil. In addition, the MELISSA (MEDICIS Laser Ion Source Setup At CERN) laser laboratory, in service since April 2019, helps to increase the separation efficiency and the selectivity. After collection, the implanted radionuclides are dispatched to the biomedical research centers, participating in the CERN-MEDICIS collaboration, for Research & Development in imaging or treatment. Since its commissioning, the CERN-MEDICIS facility has provided its partner institutes with non-conventional medical radionuclides such as Tb-149, Tb-152, Tb-155, Sm-153, Tm-165, Tm-167, Er-169, Yb-175, and Ac-225 with a high specific activity. This article provides a review of the achievements and milestones of CERN-MEDICIS since it has produced its first radioactive isotope in December 2017, with a special focus on its most recent operation in 2020.

No abstract

Abstract$$^{225}$$ 225 Ac is a radio-isotope that can be linked to biological vector molecules to treat certain distributed cancers using targeted alpha therapy. However, developing $$^{225}$$ 225 Ac-labelled radiopharmaceuticals remains a challenge due to the supply shortage of pure $$^{225}$$ 225 Ac itself. Several techniques to obtain pure $$^{225}$$ 225 Ac are being investigated, amongst which is the high-energy proton spallation of thorium or uranium combined with resonant laser ionization and mass separation. As a proof-of-principle, we perform off-line resonant ionization mass spectrometry on two samples of $$^{225}$$ 225 Ac, each with a known activity, in different chemical environments. We report overall operational collection efficiencies of 10.1(2)% and 9.9(8)% for the cases in which the $$^{225}$$ 225 Ac was deposited on a rhenium surface and a ThO$$_{2}$$ 2 mimic target matrix respectively. The bottleneck of the technique was the laser ionization efficiency, which was deduced to be 15.1(6)%.